FGFR3 amplification, which affected 5 breast cancer patients (0.5%) and 9 cases (0.5%) in the TCGA and Metabric datasets respectively, was observed in the TNBC/basal, luminal A and luminal B subtypes, with FGFR3 deep deletion mostly detected in the TNBC/basal or HER2+ subtypes (Fig. 10-10a-b). The gene discussed is ERBB2; the disease is breast carcinoma.